Key clinical point: Lenvatinib/pembrolizumab shows promise in metastatic NSCLC.
Major finding: Overall response rate at 24 weeks was 33.3%.
Study details: Interim findings in 21 patients from a phase 1b/2 study.
Disclosures: Dr. Brose has received consulting fees, research grants, and honorarium from Eisai.
Brose M et al. SITC 2018, Abstract P392
This Week's Must Reads
Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.
Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027
DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.
ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.
SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.
Must Reads in Immuno-oncology
Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392
NGS may ID SCLC candidates for immunotherapy, SITC 2018
Monalizumab + cetuximab is active in advanced SCC of the head and neck, Cohen R et al. SITC 2018, Abstract 051
Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514
Checkpoint inhibitor combo continues to show benefit for advanced melanoma, Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9